News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Phosphagenics Limited Initiates Anti-Cancer Compound Animal Trials
January 24, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Melbourne's Phosphagenics (ASX:POH, AIM:PSG) will commence animal studies later this month on its patented anti-cancer compound. More...
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Australia
MORE ON THIS TOPIC
Duchenne muscular dystrophy
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
January 26, 2026
·
2 min read
·
Dan Samorodnitsky
Ovarian cancer
Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
January 26, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Sanofi Stumbles Again in Eczema—But Plans FDA Filing for OX40 Blocker Anyway
January 23, 2026
·
2 min read
·
Tristan Manalac
Pain
Lexicon Opens Path to $1B+ Opportunity as FDA Greenlights Phase III for Non-Opioid Pill
January 22, 2026
·
2 min read
·
Tristan Manalac